The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Proteins that limit the activity of the tumour suppressor protein p53 are increasingly being targeted for inhibition in a variety of cancers. In addition to the development of small molecules, there has been interest in developing constrained (stapled) peptide inhibitors. A stapled peptide ALRN_6924 that activates p53 by preventing its interaction with its negative regulator Mdm2 has entered clinical trials. This stapled peptide mimics the interaction of p53 with Mdm2. The chances that this peptide could bind to other proteins that may also interact with the Mdm2-binding region of p53 are high; one such protein is the CREB binding protein (CBP)/p300. It has been established that phosphorylated p53 is released from Mdm2 and binds to p300, orchestrating the transcriptional program. We investigate whether molecules such as ALRN_6924 would bind to p300 and, to do so, we used molecular simulations to explore the binding of ATSP_7041, which is an analogue of ALRN_6924. Our study shows that ATSP_7041 preferentially binds to Mdm2 over p300; however, upon phosphorylation, it appears to have a higher affinity for p300. This could result in attenuation of the amount of free p300 available for interacting with p53, and hence reduce its transcriptional efficacy. Our study highlights the importance of assessing off-target effects of peptide inhibitors, particularly guided by the understanding of the networks of protein-protein interactions (PPIs) that are being targeted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, molecular simulations reveal that ATSP-7041, an analog of ALRN-6924, may bind to the p53 coactivator p300 and isolate free p300, thus reducing the transcriptional activity of p53.364”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [364]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Comparison of simple potential functions for simulating liquid water
Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983) · The Journal of Chemical Physics · doi:10.1063/1.445869 · Cited by 41,298
Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546
ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB
Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5b00255 · Cited by 10,830
Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models
Miyamoto, S., & Kollman, P. A. (1992) · Journal of Computational Chemistry · doi:10.1002/jcc.540130805 · Cited by 7,344
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Self-citationLane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Self-citationhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method
Homeyer, N., & Gohlke, H. (2012) · Molecular Informatics · doi:10.1002/minf.201100135 · Cited by 1,168
Flexible nets: The roles of intrinsic disorder in protein interaction networks
Dunker, A. K., Cortese, M. S., Romero, P., Iakoucheva, L. M., & Uversky, V. N. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04948.x · Cited by 1,122
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 1×
“The tumour suppressor protein p53 is a transcription factor that plays pivotal roles in numerous biological processes, including cell cycle arrest, apoptosis, senescence, and DNA repair [1,2]; its deregulation results in several diseases, and hence it is a major therapeutic target [3,4].”
BackgroundSelf-citationHou, T., Wang, J., Li, Y., & Wang, W. (2011) · Journal of Computational Chemistry · doi:10.1002/jcc.21666 · Cited by 761
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
Self-citationBarlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710 · cited 1×
“The next step in the activation of p53 towards its initiation of the relevant transcriptional programs is its recruitment to the histone acetyltransferase coactivators CREB binding protein (CBP) and p300, which (a) promote local chromatin unwinding [14,15] and (b) acetylate p53 on six C-terminal lysine residues furthe…”
BackgroundRecruitment of p300/CBP in p53-Dependent Signal Pathways
Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 669
Chang, Y. S., Graves, B., Guerlavais, V., Tovar, C., Packman, K., To, K.-H., Olson, K. A., Kesavan, K., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 660
p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2
Ito, A., Lai, C.-H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., & Yao, T.-P. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1331 · Cited by 582
Posttranslational Modification of p53: Cooperative Integrators of Function
Meek, D. W., & Anderson, C. W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000950 · Cited by 483
Espinosa, J. M., & Emerson, B. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00283-0 · Cited by 439
p300/MDM2 complexes participate in MDM2-mediated p53 degradation
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414 · cited 1×
“These domains are also known to interact with the N-terminal transactivation domain (TAD) of p53 [23,24].”
BackgroundHomeyer, N., Horn, A. H. C., Lanig, H., & Sticht, H. (2006) · Journal of Molecular Modeling · doi:10.1007/s00894-005-0028-4 · Cited by 394
Dyson, H. J., & Wright, P. E. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.692020 · Cited by 317
Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., & Appella, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9278 · Cited by 293
Bedford, D. C., Kasper, L. H., Fukuyama, T., & Brindle, P. K. (2010) · Epigenetics · doi:10.4161/epi.5.1.10449 · Cited by 292
p300/CBP/p53 interaction and regulation of the p53 response
Grossman, S. R. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02226.x · Cited by 263
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
García-Echeverría, C., Chène, P., Blommers, M. J. J., & Furet, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990966p · Cited by 246
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L. V., Salehi, F., Lin, D.-W., Chung, B. P., Wesley Hatfield, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 223
Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation
Lee, C. W., Ferreon, J. C., Ferreon, A. C. M., Arai, M., & Wright, P. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013078107 · Cited by 213
Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2
Ferreon, J. C., Lee, C. W., Arai, M., Martinez-Yamout, M. A., Dyson, H. J., & Wright, P. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811023106 · Cited by 210
Stapled Peptides with Improved Potency and Specificity That Activate p53
Brown, C. J., Quah, S. T., Jong, J., Goh, A. M., Chiam, P. C., Khoo, K. H., Choong, M. L., Lee, M. A., Yurlova, L., Zolghadr, K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb3005148 · Cited by 209
Self-citationFour domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53
Teufel, D. P., Freund, S. M., Bycroft, M., & Fersht, A. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702010104 · Cited by 192
Teufel, D. P., Bycroft, M., & Fersht, A. R. (2009) · Oncogene · doi:10.1038/onc.2009.71 · Cited by 159
Solution structure of the TAZ2 (CH3) domain of the transcriptional adaptor protein CBP
Guzman, R. N. D., Liu, H. Y., Martinez‐Yamout, M. A., Dyson, H. J., & Wright, P. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4141 · Cited by 149
Reactivation of p53: from peptides to small molecules
Brown, C. J., Cheok, C. F., Verma, C. S., & Lane, D. P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.004 · Cited by 149
Self-citationCandau, R., Scolnick, D. M., Darpino, P., Ying, C. Y., Halazonetis, T. D., & Berger, S. L. (1997) · Oncogene · doi:10.1038/sj.onc.1201244 · Cited by 131
Structural Basis for p300 Taz2-p53 TAD1 Binding and Modulation by Phosphorylation
Feng, H., Jenkins, L. M. M., Durell, S. R., Hayashi, R., Mazur, S. J., Cherry, S., Tropea, J. E., Miller, M., Wlodawer, A., Appella, E., et al. (2009) · Structure · doi:10.1016/j.str.2008.12.009 · Cited by 128
Krois, A. S., Ferreon, J. C., Martinez-Yamout, M. A., Dyson, H. J., & Wright, P. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602487113 · Cited by 117
Kannan, S., & Zacharias, M. (2006) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21258 · Cited by 116
Self-citationFunctional interplay between p53 and E2F through co-activator p300
Lee, C., Sørensen, T. S., Shikama, N., & Thangue, N. B. L. (1998) · Oncogene · doi:10.1038/sj.onc.1201818 · Cited by 115
Liu, G., Xia, T., & Chen, X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210696200 · Cited by 107
Factor-specific modulation of CREB-binding protein acetyltransferase activity
Perissi, V., Dasen, J. S., Kurokawa, R., Wang, Z., Korzus, E., Rose, D. W., Glass, C. K., & Rosenfeld, M. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3652 · Cited by 104
Baud, M. G. J., Bauer, M. R., Verduci, L., Dingler, F. A., Patel, K. J., Horil Roy, D., Joerger, A. C., & Fersht, A. R. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.035 · Cited by 94
HCMV IE2‐mediated inhibition of HAT activity downregulates p53 function
Hsu, C.-H., Chang, M. D., Tai, K., Yang, Y.-T., Wang, P.-S., Chen, C., Wang, Y., Lee, S.-C., Wu, C., & Juan, L. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600239 · Cited by 90
Meek, D. W., & Hupp, T. R. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.005 · Cited by 76
Jenkins, L. M. M., Yamaguchi, H., Hayashi, R., Cherry, S., Tropea, J. E., Miller, M., Wlodawer, A., Appella, E., & Mazur, S. J. (2009) · Biochemistry · doi:10.1021/bi801716h · Cited by 63
Partridge, A. W., Kaan, H. Y. K., Juang, Y.-C. A., Sadruddin, A., Lim, S., Brown, C. J., Ng, S., Thean, D., Ferrer, F. J., Johannes, C. W., et al. (2019) · Molecules · doi:10.3390/molecules24122292 · Cited by 57
Self-citationExploiting the p53 Pathway for Therapy
Cheok, C. F., & Lane, D. P. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026310 · Cited by 52
Self-citationModulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study
Lee, H. J., Srinivasan, D., Coomber, D., Lane, D. P., & Verma, C. S. (2007) · Cell Cycle · doi:10.4161/cc.6.21.4923 · Cited by 48
Self-citationIdentifying long-range structure in the intrinsically unstructured transactivation domain of p53
Vise, P., Baral, B., Stancik, A., Lowry, D. F., & Daughdrill, G. W. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21364 · Cited by 47
Benzene Probes in Molecular Dynamics Simulations Reveal Novel Binding Sites for Ligand Design
Tan, Y. S., Reeks, J., Brown, C. J., Thean, D., Ferrer‐Gago, F. J., Yuen, T. Y., Goh, E. T. L., Lee, X. C., Jennings, C., Joseph, T. L., et al. (2016) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.6b01525 · Cited by 42
Self-citationDifferential Recognition of Phosphorylated Transactivation Domains of p53 by Different p300 Domains
Polley, S., Guha, S., Roy, N. S., Kar, S., Sakaguchi, K., Chuman, Y., Swaminathan, V., Kundu, T. K., & Roy, S. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.11.082 · Cited by 37
Tan, Y. S., Mhoumadi, Y., & Verma, C. S. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz009 · Cited by 34
Self-citationKinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2
Yadahalli, S., Neira, J. L., Johnson, C. M., Tan, Y. S., Rowling, P. J. E., Chattopadhyay, A., Verma, C. S., & Itzhaki, L. S. (2019) · Scientific Reports · doi:10.1038/s41598-018-36589-5 · Cited by 34
Self-citationOstermeir, K., & Zacharias, M. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23476 · Cited by 33
Research works printed but not linked: 1
- Scolnick, 1997, CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein, Cancer Res., 57, 3693
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Metadata
- Authors
- Kannan, S., Partridge, A. W., Lane, D. P., & Verma, C. S.
- Affiliations
- Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, #07-01 Matrix, Singapore 138671, Singapore
- MSD International, Translation Medicine Research Centre, Singapore 138665, Singapore
- p53 Laboratory, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, #06-04/05, Neuros/Immunos, Singapore 138648, Singapore
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-28
- Volume
- 20
- Issue
- 23
- Pages
- 5996
- ISSN
- 1422-0067
- Cited by
- 17
- References
- 60
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.